Navigation Links
Reliability and benefit of diagnostic procedure for asthma in young children is unclear
Date:8/20/2009

This release is available in German.

The Institute for Quality and Efficiency in Health Care (IQWiG) has investigated the reliability of diagnosing bronchial asthma in children aged between 2 and 5 years, and the benefit that the test results can have for these patients. IQWiG published its final report in August 2009. According to the report, the available studies do not reveal any diagnostic procedure to be particularly suitable. It also remains unclear whether the treatment given based on the test results can benefit the patients.

The Federal Joint Committee (G-BA) commissioned the Institute to carry out the research. Using IQWiG expertise, the committee seeks an answer to the question whether the existing DMP should be extended to children of preschool age. Until now, it has only been possible to enrol children from the age of 5 upwards on a DMP.

Diagnosis must be certain

Bronchial asthma frequently starts in early childhood, but it is very difficult to diagnose in this age group. Moreover, young children are often free of symptoms by the time they reach school age. On the one hand, the screening should ensure no asthma cases are overlooked, so that appropriate treatment can be given in good time. On the other hand, children that do not actually suffer from chronic asthma should not receive unnecessary treatment and thus be exposed to potential harm. The certainty of the diagnosis is therefore of particular importance.

In the first report already completed, IQWiG investigated whether a reference standard could be derived from clinical practice guidelines, against which the diagnostic reliability of individual methods could be measured. The current optimum and most reliable method for diagnosing or excluding a disease is taken as a reference standard. As this type of test could not be identified, the Institute then investigated the accuracy of diagnostic procedures without using a reference standard.

No recommendation for diagnostic procedures can be derived from studies

In this second part of the commission, IQWiG investigated how suitable the procedures are in differentiating between those children who have symptoms but do not require long-term treatment and those children who develop chronic asthma. This ability to discriminate and predict is particularly important for those children who might have to be enrolled on a DMP.

After analysing a total of 7 studies available at that time, IQWiG came to the conclusion that the literature could not provide any recommendations for an individual method, or a combination of specific methods, that could be used as a criterion for enrolment on a DMP. The superiority of one test over any other could not be established.

This is firstly because there are only a few clinical comparisons dealing with the commission's research question. Secondly, the data contained in them have no validity, because the study and report quality displayed flaws. For example, there is a lack of data on the severity of disease in the patients examined, yet the degree of severity can have an influence on how reliably the test confirms the disease. The analysed studies indicate that a diagnostic algorithm could be used, i.e. a certain sequence in which individual measures can be combined together.

"Linked evidence" method could not be applied

In order to assess the diagnostic procedures, IQWiG also evaluated their efficacy. The tests can only be described as efficacious if they result in a therapeutic benefit, i.e. the patients can benefit from treatment. However, as the search revealed, there are currently no diagnostic studies that could provide a direct answer to the question of test efficacy (Phase 4 diagnostic studies), because this would require a study design that investigates a treatment strategy consisting of a test and an intervention.

If information on diagnostic procedures and therapeutic measures is only available in separate studies (Phase 2 and 3 diagnostic studies, and therapy studies), it is possible to try to synthesize and link them to a certain extent. In this way, at least indirect findings on the clinical efficacy of diagnostic procedures can be obtained. However, this method of "linked evidence" involves certain methodological requirements. As IQWiG and its external experts established, the studies available to date on diagnosing asthma in children under 5 years of age do not contain these requirements. Thus, a reference standard was particularly lacking.

No robust conclusions concerning efficacy possible

Even a modified procedure which, based on the linked evidence criteria, attempts to link the studies without a reference test is not possible. This is in part because the asthma-specific selection criteria are not precisely described in the therapy studies. Furthermore, none of the therapy studies used a selection method whose diagnostic accuracy had already been proven by studies.

IQWiG has therefore concluded that the results from the diagnostic and therapy studies cannot actually be synthesized in terms of "linked evidence". No robust conclusions can be drawn concerning the accuracy of individual tests used in therapy studies nor on the clinical efficacy of interventions tested in Phase 2 and 3 diagnosis studies.

Report preparation stage

IQWiG published the preliminary results in two separate preliminary reports in June (Part 1) and in September (Part 2) 2008 and interested parties were invited to submit comments. When the comments stage ended, the two preliminary reports were revised and then compiled into a final report, which was sent to the contracting agency at the beginning of June 2009. Documentation of the written comments for both preliminary reports and the minutes of the hearing procedure are published in a separate document simultaneously with the final report. The report was produced in collaboration with external experts.

Research question comprehensively answered in three final reports

This final report completes the commission package. Using IQWiG expertise, the G-BA can now advise on whether or not the Asthma DMP should be extended to children under 5 years of age.

In the first part of the commission, IQWiG examined whether there was a generally recognized procedure for diagnosing asthma in children. However, the final report came to the conclusion that such a reference standard did not exist. In the second part of the commission, IQWiG therefore had to investigate the accuracy of diagnostic procedures without reference to a comparison test. The results were presented here in detail: firstly, it is not possible to recommend a specific test as a basis for registering on a DMP; secondly, it is not possible to draw robust conclusions on whether, based on the test, young children could then receive treatment that would provide them with a benefit.

In the third part of the commission, IQWiG assessed the benefit of drug and non-drug interventions. As IQWiG has confirmed, it remains unclear whether 2 to 4-year-olds benefit from measures, which up till now have only been offered to children aged 5 upwards as part of the Asthma DMP, for suitable interventions for preschool children have not been adequately investigated. A few studies indicate that the drug, fluticasone propionate (ICS), approved for children aged 4 upwards, can lower the rate of acute exacerbations and increase the number of asthma-free days. However, it can also cause growth retardation.

An overview of the background, methods and further results of the final report on the reliability and benefit of diagnostic procedures is provided by an Executive Summary.


'/>"/>

Contact: Dr. Anna-Sabine Ernst
info@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Study examines reliability of clinical and pathological diagnoses of Barretts esophagus
2. Study tests reliability of more accurate measure of patient pain
3. Study suggests reliability of cognitive assessment tool varies widely
4. Reliability & Confidence Define a Nation Of It Girls
5. Miami-Area Experienced Fewer Fluctuations in Pharmacy Benefit Enrollment Than Other Florida Markets
6. Palliative care intervention for patients with advanced cancer provides quality of life benefits
7. Retirees health-care benefits at risk, study warns
8. Chemo Plus Palliative Care Reaps Benefits
9. CA$H-First(SM) LTCi Provides First-Day Cash Benefits at Affordable Rates
10. Free Online Tools Benefitting Time-Starved, Cost-Conscious Home Cooks
11. Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: